

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 7, 2026

VEGA

RRID:SCR_007907

Type: Tool

Proper Citation

VEGA (RRID:SCR_007907)

Resource Information

URL: <http://vega.sanger.ac.uk/>

Proper Citation: VEGA (RRID:SCR_007907)

Description: Central repository for high quality frequently updated manual annotation of vertebrate finished genome sequence. Human, mouse and zebrafish are in the process of being completely annotated, whereas for other species the annotation is only of specific genomic regions of particular biological interest. The majority of the annotation is from the HAVANA group at the Wellcome Trust Sanger Institute. Users can BLAST, search for specific text, export, and download data. Genomes and details of the projects for each species are available through the homepages for human mouse and zebrafish. The website is built upon code from the Ensembl (<http://www.ensembl.org>) project. Some Ensembl features are not available in Vega. From the users point of view perhaps the most significant of these is MartView. However due to their inclusion in Ensembl, Vega human and mouse data can be queried using Ensembl MartView. Vega contains annotation of the human MHC region in eight haplotypes, and the LRC region in three haplotypes. Vega also contains annotation on the Insulin Dependent Diabetes (IDD) regions on non-reference assemblies for mouse.

Abbreviations: VEGA

Synonyms: The Vertebrate Genome Annotation database (VEGA), Vertebrate Genome Annotation, Vertebrate Genome Annotation Database

Resource Type: analysis service resource, data analysis service, data or information resource, database, production service resource, service resource

Defining Citation: [PMID:18003653](#), [PMID:15975227](#), [PMID:15608237](#)

Keywords: human, mouse, zebrafish, gorilla, wallaby, pig, dog, vertebrate, genome, orfs, FASEB list

Resource Name: VEGA

Resource ID: SCR_007907

Alternate IDs: r3d100012575

Alternate URLs: <https://doi.org/10.17616/R3W77X>

Record Creation Time: 20220129T080244+0000

Record Last Update: 20260905T132615+0000

Ratings and Alerts

No rating or validation information has been found for VEGA.

No alerts have been found for VEGA.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 765 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Fayyaz S, et al. (2026) Reassessing the carcinogenic potential of dibutyl hydrogen phosphate: new insight from repeated-dose toxicity studies. Archives of toxicology, 100(5), 2111.

Delre P, et al. (2026) VeGA-RX and VeGA-SCX: Controllable SMARTS-Guided Generative Transformers for Precision-Driven De Novo Drug Design. Journal of chemical information and modeling, 66(9), 5189.

Dos Santos ME, et al. (2026) Functional architecture and cell wall composition of peltate scales involved in leaf water absorption. Frontiers in plant science, 17, 1756403.

Bygdell M, et al. (2026) Change in healthcare utilization before and after COVID-19 using data from 1.5 million individuals. Journal of internal medicine, 299(2), 255.

Edizcan Z, et al. (2026) High-throughput PBK modelling for dermal exposure: a pragmatic approach to predict systemic pharmacokinetics. Archives of toxicology, 100(6), 2421.

Juliana CA, et al. (2026) Functional evaluation of pancreatic islets from patients with Beckwith-Wiedemann syndrome and congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 111(7), 1874.

Harvey BP, et al. (2026) Group-based trajectory modelling of multiple health outcomes in a cost-consequence framework: a randomized controlled trial of a remote person-centred care intervention for people with common mental disorders in Sweden. Journal of patient-

reported outcomes, 10(1).

Emesu G, et al. (2026) Equity in awareness and utilization of cervical cancer screening services among women of reproductive age in Uganda: Analysis of vertical equity using evidence from UDHS 2022. *PloS one*, 21(4), e0335336.

Malarvizhi GL, et al. (2025) Rationally Designed Functionalized Phytochemical-Conjugated Fullerene Quantum Dots Inhibiting Viral Chaperone Activity and RNA-Dependent RNA Polymerase in Nipah Virus. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(15), e70890.

Gafforov Y, et al. (2025) Bioactivity profiling of *Sanghuangporus lonicerinus*: antioxidant, hypoglycaemic, and anticancer potential via in-vitro and in-silico approaches. *Journal of enzyme inhibition and medicinal chemistry*, 40(1), 2461185.

Drivelegka P, et al. (2025) Allopurinol use and risk of acute coronary syndrome in gout patients: a population-based cohort study in Sweden. *BMJ open*, 15(2), e092522.

Rafsten L, et al. (2025) Gothenburg very early supported discharge: evaluating differences in costs and environmental impact due to rehabilitation consumption during the first year in patients hospitalized due to mild stroke. *BMC health services research*, 25(1), 406.

Adamczyk O, et al. (2025) Electrospun Fiber Mats with Metronidazole: Design, Evaluation, and Release Kinetics. *The journal of physical chemistry. B*, 129(18), 4535.

Chen X, et al. (2025) Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008-2017. *ESC heart failure*, 12(2), 832.

Krishnan S, et al. (2025) Fractional inhibitory concentration of bio-actives from agricultural waste disassembles biofilms and quenches virulence of nosocomial pathogens. *Journal of medical microbiology*, 74(3).

Jung T, et al. (2025) Vibration-Induced Stabilization of Lithium Anodes: Synergistic Effects of Morphological and SEI Evolution. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(26), e2502192.

Builee T, et al. (2025) Characterization of medical device constituents and development of duration-based non-cancer threshold of toxicological concern values. *Frontiers in toxicology*, 7, 1600127.

Abedi E, et al. (2025) A machine learning tool for identifying metastatic colorectal cancer in primary care. *Scandinavian journal of primary health care*, 43(3), 585.

Pradeep P, et al. (2025) Applicability of In Silico New Approach Methods for the Risk Assessment of Tattoo Ink Ingredients. *Environmental and molecular mutagenesis*, 66(4), 199.

Tafazoli A, et al. (2025) Leveraging long-read sequencing technologies for pharmacogenomic testing: applications, analytical strategies, challenges, and future perspectives. *Frontiers in genetics*, 16, 1435416.